Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics
I'm PortAI, I can summarize articles.
Johnson & Johnson has finalized its $3.05 billion acquisition of Halda Therapeutics, enhancing its portfolio with innovative therapies for solid tumors, including prostate cancer. The deal is expected to dilute Adjusted Earnings Per Share by approximately $0.20 across 2025 and 2026 due to related costs. Further guidance for 2026 will be provided during the fourth quarter earnings call in January 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments